Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
3 participants
INTERVENTIONAL
2022-01-07
2022-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Endometrial Effects of Daily Progesterone s.c. 25 and 50 Mg Aqueous Formulation to Female Healthy Volunteers
NCT00377923
Pharmacodynamic Characterization of Dienogest
NCT00754871
Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods
NCT02456584
Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vaginal Insert
NCT06668896
Investigation of Female Reproductive Hormone Dynamics During Adolescence
NCT02486757
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vaginal progesterone
200mg micronized vaginal progesterone placed 7am prior to scheduled cesarean delivery
micronized Progesterone
200mg micronized progesterone placed vaginally
Control
No intervention, scheduled cesarean delivery
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
micronized Progesterone
200mg micronized progesterone placed vaginally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Singleton gestation, ≥36 0/7 weeks gestation
* Scheduled cesarean delivery at Thomas Jefferson University Hospital or affiliate
Exclusion Criteria
* Active hepatic disease
* Prior or current thrombus
* Known adverse reaction to progesterone
* Peanut allergy
* Bleeding disorder (such as thrombophilia)
* Use of 17-hydroxyprogesterone caproate in the pregnancy
* Use of vaginal progesterone in the pregnancy
* History of adverse reaction to progesterone
* Current vaginitis
16 Years
55 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Thomas Jefferson University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20D.1094
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.